Feladilimab, also as GSK3359609, represents a significant advance in immunotherapy treatment. This engineered monoclonal antibody uniquely targets {CD47|, the "don't eat me" signal, a protein expressed on several cell https://diegohncj135233.blog5.net/92062170/feladilimab-gsk3359609-a-deep-analysis-into-the-groundbreaking-antibody